Heron Therapeutics, Inc. (HRTX) Earnings Call Transcripts

19 earnings calls from November 2021 to August 10, 2026

NASDAQ US Health Care Biotechnology

Heron Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Heron Therapeutics reported net revenues of $34.7 million, slightly below expectations due to seasonal headwinds and severe weather impacting elective surgeries. The company maintained its full-year guidance of $173 million to $183 million in net product sales and adjusted EBITDA of $10 million to $20 million. Management highlighted a strong recovery in March with net sales exceeding $15 million, indicating potential for improved performance in the upcoming quarters.

Reported metrics

MetricValueContext
Net Revenue $34.7 million (miss) vs $36 million est, -5% YoY
Gross Margin 69% (negative) below typical low to mid-70s range
Adjusted EBITDA -$727,000 (miss) reflecting storm-related revenue softness
ZYNRELEF Revenue Growth 27% (positive) year-over-year growth
APONVIE Revenue Growth over 50% (positive) year-over-year growth
CINVANTI Market Share 25% (inline) consistent with 12-month average

Guidance from management

Heron maintained its full-year guidance for net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, indicating confidence in recovery as elective procedures are rescheduled throughout the year.

What management said

Brandon, I appreciate those questions. I'll begin with the Baxter settlement, after which I'll hand things to Mark. Given what the settlement stipulates, we truly cannot elaborate on it beyond noting the dates and all other information already made public; apart from that, we are simply prohibited from commenting further on it; therefore I'll pass it to Mark so he can address the ZYNRELEF topics you raised.
— Craig Collard, Q1 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns regarding the impact of severe weather on surgical volumes and how this might affect future sales. There were also questions about the effectiveness of the IGNITE program and how management plans to overcome adoption friction for ZYNRELEF and APONVIE.

Main topics on the call

Read the full Heron Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. (HRTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 19 calls on record spanning November 3, 2021 to August 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.

Earnings Call History

EarningsCalls.dev has 19 Heron Therapeutics, Inc. earnings call transcripts on record, spanning November 3, 2021 to August 10, 2026. Based on this history, Heron Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the transcript.

Ticker
HRTX
Exchange
NASDAQ
Country
US
Sector
Health Care
Industry
Biotechnology
Calls on record
19
First call
November 3, 2021
Most recent
August 10, 2026
Reporting cadence
quarterly
Quarter Date
Q2 FY2026 Aug 10, 2026 Read transcript →
Q1 FY2026 May 11, 2026 Read transcript →
Q4 FY2025 Feb 26, 2026 Read transcript →
Q3 FY2025 Nov 4, 2025 Read transcript →
Q2 FY2025 Aug 8, 2025 Read transcript →
Q4 FY2024 Feb 27, 2025 Read transcript →
Q3 FY2024 Nov 12, 2024 Read transcript →
Q2 FY2024 Aug 6, 2024 Read transcript →
Q1 FY2024 May 7, 2024 Read transcript →
Q4 FY2023 Mar 12, 2024 Read transcript →
Q3 FY2023 Nov 14, 2023 Read transcript →
Q2 FY2023 Aug 14, 2023 Read transcript →
Q1 FY2023 May 11, 2023 Read transcript →
Q4 FY2022 Mar 23, 2023 Read transcript →
Q3 FY2022 Nov 8, 2022 Read transcript →
Q2 FY2022 Aug 9, 2022 Read transcript →
Q1 FY2022 May 9, 2022 Read transcript →
Q4 FY2021 Feb 28, 2022 Read transcript →
Q3 FY2021 Nov 3, 2021 Read transcript →